title: Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment.
abstract: Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseases with neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumab or ranibizumab is superior. A 32-year-old female diagnosed with herpetic keratoconjunctivitis with refractory corneal NV despite two previous subconjunctival and intrastromal bevacizumab injections, received two subconjunctival and intrastromal ranibizumab injections. Six months postoperatively, there was significant regression of the neovascular area and vessel caliber. Here, the authors report a case of improvement in corneal NV with subconjunctival and intrastromal ranibizumab injections, which was previously refractory to bevacizumab injection. The findings may suggest a new prospect in treating corneal NV.
authors.affiliation: Department of Ophthalmology and Visual Science, Yeouido St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
authors.forename: Ye Jin
authors.initials: YJ
authors.lastname: Ahn
authors.affiliation: Department of Ophthalmology and Visual Science, Yeouido St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
authors.forename: Hyung Bin
authors.initials: HB
authors.lastname: Hwang
authors.affiliation: Department of Ophthalmology and Visual Science, Yeouido St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
authors.forename: Sung Kun
authors.initials: SK
authors.lastname: Chung
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D003228:Conjunctiva / Q000098:blood supply; D016510:Corneal Neovascularization / Q000188:drug therapy*; D003319:Corneal Stroma / Q000098:blood supply; D005260:Female; D006801:Humans; D056965:Injections, Intraocular / Q000379:methods; D016849:Keratitis, Herpetic / Q000188:drug therapy*; D000069579:Ranibizumab; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab
keywords: Corneal neovascularization; Herpetic keratitis; Ranibizumab; Subconjunctival and intrastromal injections